Dr Patrick Harris
Dr

Patrick Harris

Email: 
Phone: 
+61 7 334 65476

Background

Dr Patrick Harris is an Infectious Disease Physician, Medical Microbiologist and NHMRC Emerging Leader (EL2) Fellow at The University of Queensland Centre for Clinical Research (UQCCR).

Dr. Harris obtained a BSc in Psychology and Anthropology from Durham University, prior to acquiring his medical degree from University College London Medical School. Following postgraduate training in the UK, he worked as a clinical lecturer at the College of Medicine in Malawi, before completing specialist training in infectious diseases and microbiology in Australia. For his final year of training he was a Senior Visiting Fellow in Infectious Disease at the National University Hospital in Singapore. He completed his PhD in 2018 under the supervision of Prof. David Paterson, and now is a Group Leader at UQCCR, with a research focus on the diagnosis and clinical management of infections caused by multi-drug resistant bacteria

Availability

Dr Patrick Harris is:
Available for supervision

Qualifications

  • Bachelor of Medicine and Surgery and Medical Science, University of London
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Clinical trials

    Assessing the clinical impact of novel antibiotic treatment strategies for bloodstream infections

  • Antibiotic resistance

    Resistance in gram-negative pathogens such as E. coli, Klebsiella and Enterobacter

  • Clinical application of genomics

    Use of whole genome sequencing in clinical microbiology

Research impacts

He has published more than 200 peer-reviewed articles, many as first or senior author, including JAMA, the Lancet, Lancet Infectious Diseases and Clinical Infectious Diseases. He was a lead investigator for the MERINO trial: an international multicentre study to compare carbapenem-sparing treatment options for ESBL and AmpC-producing species. This has been the first large RCT to specifically address this question, using a protocol developed and endorsed by the Australasian Society for Infectious Diseases Clinical Research Network (ASID-CRN). https://clinicaltrials.gov/ct2/show/NCT02176122. This was followed by the MERINO-2 trial: a randomised controlled trial of meropenem versus piperacillin-tazobactam for treatment of bloodstream infections due to AmpC-producing Enterobacter, Citrobacter, Serratia, Providencia and Morganella: https://clinicaltrials.gov/ct2/show/NCT02437045. His other main research interest includes the application of whole genome sequencing to clinical microbiology. He was the clinical lead for the Queensland Genomics Clinical Demonstration Project: Whole genome sequencing to track, treat and prevent nosocomial infections. This project has successfuly integrated a genomics workflow within Queensland health, to support outbreak response and surveillance of hospital acqured multi-drug resistant infections: Hospital acquired infections – Queensland Genomics

Search Professor Patrick Harris’s works on UQ eSpace

269 works between 2009 and 2025
All (269) Journal Article (240) Other Outputs (3) Conference Publication (24) Book Chapter (2)

41 - 60 of 269 works

2024

Journal Article

Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis

Chai, Gene G., Tu, Quyen, Cotta, Menino O., Bauer, Michelle J., Balch, Ross, Okafor, Charles, Comans, Tracy, Kruger, Peter, Meyer, Jason, Shekar, Kiran, Brady, Kara, Fourie, Cheryl, Sharp, Natalie, Vlad, Luminita, Whiley, David, Ungerer, Jacobus P. J., McWhinney, Brett C., Farkas, Andras, Paterson, David L., Clark, Julia E., Hajkowicz, Krispin, Raman, Sainath, Bialasiewicz, Seweryn, Lipman, Jeffrey, Forde, Brian M., Harris, Patrick N. A., Schlapbach, Luregn J., Coin, Lachlan, Roberts, Jason A. and Irwin, Adam D. (2024). Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis. Intensive Care Medicine, 50 (4), 539-547. doi: 10.1007/s00134-024-07353-3

Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis

2024

Journal Article

Time to positivity is a risk factor for death among patients with bloodstream infections: a population-based cohort

Laupland, Kevin B., Edwards, Felicity, Dettrick, Zoe and Harris, Patrick N.A. (2024). Time to positivity is a risk factor for death among patients with bloodstream infections: a population-based cohort. Clinical Microbiology and Infection, 30 (7), 899-904. doi: 10.1016/j.cmi.2024.03.032

Time to positivity is a risk factor for death among patients with bloodstream infections: a population-based cohort

2024

Journal Article

Persistence of detectable pathogens by culture independent systems (T2 Magnetic Resonance) in patients with bloodstream infection: prognostic role and possible clinical implications

Peri, Anna Maria, O’Callaghan, Kevin, Rafiei, Nastaran, Graves, Bianca, Sinclair, Holly, Brischetto, Anna, Lim, Karen, Parkes-Smith, Jill, Eustace, Matthew, Davidson, Natalie, Tabah, Alexis, Stewart, Adam, Chatfield, Mark D., Harris, Patrick N.A. and Paterson, David L. (2024). Persistence of detectable pathogens by culture independent systems (T2 Magnetic Resonance) in patients with bloodstream infection: prognostic role and possible clinical implications. Clinical Infectious Diseases, 78 (2), 283-291. doi: 10.1093/cid/ciad663

Persistence of detectable pathogens by culture independent systems (T2 Magnetic Resonance) in patients with bloodstream infection: prognostic role and possible clinical implications

2024

Journal Article

HAIviz: an interactive dashboard for visualising and integrating healthcare-associated genomic epidemiological data

Permana, Budi, Harris, Patrick N. A., Roberts, Leah W., Cuddihy, Thom, Paterson, David L., Beatson, Scott A. and Forde, Brian M. (2024). HAIviz: an interactive dashboard for visualising and integrating healthcare-associated genomic epidemiological data. Microbial Genomics, 10 (2) 001200. doi: 10.1099/mgen.0.001200

HAIviz: an interactive dashboard for visualising and integrating healthcare-associated genomic epidemiological data

2024

Journal Article

Win ratio analyses of piperacillin-tazobactam versus meropenem for ceftriaxone non-susceptible Escherichia coli or Klebsiella pneumoniae bloodstream infections: Post-hoc insights from the MERINO trial

Hardy, Melissa, Harris, Patrick N. A., Paterson, David L., Chatfield, Mark D., Mo, Yin, for the MERINO trial investigators, Tambyah, Paul A., Lye, David C., Lee, Tau H., Yilmaz, Mesut, Alenazi, Thamer H., Arabi, Yaseen, Falcone, Marco, Bassetti, Matteo, Righi, Elda, Rogers, Benjamin A., Kanj, Souha, Bhally, Hasan, Iredell, Jon, Mendelson, Marc, Boyles, Tom H., Looke, David, Miyakis, Spiros, Walls, Genevieve, Al Khamis, Mohammed, Zikri, Ahmed, Crowe, Amy, Ingram, Paul, Daneman, Nick ... Peleg, Anton Y. (2024). Win ratio analyses of piperacillin-tazobactam versus meropenem for ceftriaxone non-susceptible Escherichia coli or Klebsiella pneumoniae bloodstream infections: Post-hoc insights from the MERINO trial. Clinical Infectious Diseases, 78 (6), 1482-1489. doi: 10.1093/cid/ciae050

Win ratio analyses of piperacillin-tazobactam versus meropenem for ceftriaxone non-susceptible Escherichia coli or Klebsiella pneumoniae bloodstream infections: Post-hoc insights from the MERINO trial

2024

Conference Publication

The molecular epidemiology of Burkholderia pseudomallei in North Queensland

Gassiep, Ian, Burnard, Delaney, Permana, Budi, Bauer, Michelle J., Cuddihy, Thom, Forde, Brian M., Chatfield, Mark D., Ling, Weiping, Mayer-Coverdale, Johanna, Norton, Robert and Harris, Patrick N.A. (2024). The molecular epidemiology of Burkholderia pseudomallei in North Queensland. Pathology Update 2024, Adelaide, VIC, Australia, 1 - 3 March 2024. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.pathol.2023.12.133

The molecular epidemiology of Burkholderia pseudomallei in North Queensland

2024

Journal Article

Scoping review of risk-scoring tools for early prediction of bloodstream infections caused by carbapenem-resistant Enterobacterales: do we really have a reliable risk-scoring tool?

Aslan, Abdullah Tarik, Ezure, Yukiko, Harris, Patrick N. A. and Paterson, David L. (2024). Scoping review of risk-scoring tools for early prediction of bloodstream infections caused by carbapenem-resistant Enterobacterales: do we really have a reliable risk-scoring tool?. JAC-Antimicrobial Resistance, 6 (1) dlae032, 1-9. doi: 10.1093/jacamr/dlae032

Scoping review of risk-scoring tools for early prediction of bloodstream infections caused by carbapenem-resistant Enterobacterales: do we really have a reliable risk-scoring tool?

2024

Journal Article

The global epidemiology of ventilator-associated pneumonia caused by multi-drug resistant Pseudomonas aeruginosa: a systematic review and meta-analysis

Li, Yixuan, Roberts, Jason A., Walker, Mikaela M., Aslan, Abdullah Tarik, Harris, Patrick N. A. and Sime, Fekade (2024). The global epidemiology of ventilator-associated pneumonia caused by multi-drug resistant Pseudomonas aeruginosa: a systematic review and meta-analysis. International Journal of Infectious Diseases, 139, 78-85. doi: 10.1016/j.ijid.2023.11.023

The global epidemiology of ventilator-associated pneumonia caused by multi-drug resistant Pseudomonas aeruginosa: a systematic review and meta-analysis

2024

Journal Article

Differences in antimicrobial resistance gene abundance and microbial diversity of the gut microbiome in patients on antibiotics enrolled in a clinical trial

Stewart, Adam G., Harris, Patrick N.A., Graham, Rikki M.A., Jennison, Amy V., Schlebusch, Sanmarie, Harris-Brown, Tiffany, Paterson, David L. and Forde, Brian M. (2024). Differences in antimicrobial resistance gene abundance and microbial diversity of the gut microbiome in patients on antibiotics enrolled in a clinical trial. Pathology, 56, S36-S37. doi: 10.1016/j.pathol.2023.12.137

Differences in antimicrobial resistance gene abundance and microbial diversity of the gut microbiome in patients on antibiotics enrolled in a clinical trial

2024

Journal Article

Rapid nanopore sequencing and predictive susceptibility testing of positive blood cultures from intensive care patients with sepsis

Harris, Patrick N. A., Bauer, Michelle J., Lüftinger, Lukas, Beisken, Stephan, Forde, Brian M., Balch, Ross, Cotta, Menino, Schlapbach, Luregn, Raman, Sainath, Shekar, Kiran, Kruger, Peter, Lipman, Jeff, Bialasiewicz, Seweryn, Coin, Lachlan, Roberts, Jason A., Paterson, David L. and Irwin, Adam D. (2024). Rapid nanopore sequencing and predictive susceptibility testing of positive blood cultures from intensive care patients with sepsis. Microbiology Spectrum, 12 (2) e0306523, 1-16. doi: 10.1128/spectrum.03065-23

Rapid nanopore sequencing and predictive susceptibility testing of positive blood cultures from intensive care patients with sepsis

2024

Journal Article

Vibrio species bloodstream infections in Queensland, Australia

Davidson, Natalie, Edwards, Felicity, Harris, Patrick N.A. and Laupland, Kevin B. (2024). Vibrio species bloodstream infections in Queensland, Australia. Internal Medicine Journal, 54 (1), 157-163. doi: 10.1111/imj.16187

Vibrio species bloodstream infections in Queensland, Australia

2024

Journal Article

Mortality, hospital length of stay and recurrent bloodstream infections associated with extended-spectrum beta-lactamase producing Escherichia coli (ESBL-Ec) in a low prevalence region: a 20-year population-based large cohort study

Ling, Weiping, Paterson, David L., Harris, Patrick N. A., Furuya-Kanamori, Luis, Edwards, Felicity and Laupland, Kevin B. (2024). Mortality, hospital length of stay and recurrent bloodstream infections associated with extended-spectrum beta-lactamase producing Escherichia coli (ESBL-Ec) in a low prevalence region: a 20-year population-based large cohort study. International Journal of Infectious Diseases, 138, 84-90. doi: 10.1016/j.ijid.2023.11.007

Mortality, hospital length of stay and recurrent bloodstream infections associated with extended-spectrum beta-lactamase producing Escherichia coli (ESBL-Ec) in a low prevalence region: a 20-year population-based large cohort study

2024

Journal Article

Host response signature trends in bacteraemia–authors’ response

Peri, Anna Maria, Harris, Patrick N. A. and Paterson, David L. (2024). Host response signature trends in bacteraemia–authors’ response. Infectious Diseases, 56 (5), 1-3. doi: 10.1080/23744235.2024.2326591

Host response signature trends in bacteraemia–authors’ response

2023

Journal Article

Host response signature trends in persistent bacteraemia and metastatic infection due to Staphylococcus aureus and Gram-negative bacilli: a prospective multicentre observational study

Peri, Anna Maria, Rafiei, Nastaran, O’Callaghan, Kevin, Brischetto, Anna, Graves, Bianca, Sinclair, Holly, Eustace, Matthew, Lim, Karen, Parkes-Smith, Jill, Stewart, Adam, Davidson, Natalie, Tabah, Alexis, Bergh, Haakon, Chatfield, Mark D., Harris, Patrick N. A. and Paterson, David L. (2023). Host response signature trends in persistent bacteraemia and metastatic infection due to Staphylococcus aureus and Gram-negative bacilli: a prospective multicentre observational study. Infectious Diseases, 56 (4), 268-276. doi: 10.1080/23744235.2023.2294122

Host response signature trends in persistent bacteraemia and metastatic infection due to Staphylococcus aureus and Gram-negative bacilli: a prospective multicentre observational study

2023

Journal Article

Evaluation of Illumina® COVIDSeq™ as a Tool for Omicron SARS-CoV-2 Characterisation

Lowry, Kym, Bauer, Michelle J., Buckley, Cameron, Wang, Claire, Bordin, Amanda, Badman, Steven, Harris, Patrick N.A., Mackay, Ian and Whiley, David (2023). Evaluation of Illumina® COVIDSeq™ as a Tool for Omicron SARS-CoV-2 Characterisation. Journal of Virological Methods, 322 114827, 1-5. doi: 10.1016/j.jviromet.2023.114827

Evaluation of Illumina® COVIDSeq™ as a Tool for Omicron SARS-CoV-2 Characterisation

2023

Journal Article

Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales

Tamma, Pranita D., Harris, Patrick N. A., Mathers, Amy J., Wenzler, Eric and Humphries, Romney M. (2023). Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales. Clinical Infectious Diseases, 77 (11), 1585-1590. doi: 10.1093/cid/ciac688

Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales

2023

Conference Publication

Elizabethkingia species: an emerging cause of healthcare-associated bloodstream infection among immunocompromised hosts

Stewart, Adam, Laupland, Kevin, Edwards, Felicity, Paterson, David and Harris, Patrick N. A. (2023). Elizabethkingia species: an emerging cause of healthcare-associated bloodstream infection among immunocompromised hosts. IDWeek 2023, Boston, MA USA, 11-15 October 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ofid/ofad500.310

Elizabethkingia species: an emerging cause of healthcare-associated bloodstream infection among immunocompromised hosts

2023

Conference Publication

Assessment of in vitro synergy between piperacillin-tazobactam-meropenem and imipenem-meropenem against OXA-48 producing Klebsiella pneumoniae using time-kill assays

Demir, Mervenur, Aslan, Abdullah Tarik, Seren Tanrıverdi, Elif, Otlu, Barış, Akova, Murat, Paterson, David, Harris, Patrick N. A. and Hazırolan, Gülşen (2023). Assessment of in vitro synergy between piperacillin-tazobactam-meropenem and imipenem-meropenem against OXA-48 producing Klebsiella pneumoniae using time-kill assays. IDWeek 2023, Boston, MA USA, 11-15 October 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ofid/ofad500.2357

Assessment of in vitro synergy between piperacillin-tazobactam-meropenem and imipenem-meropenem against OXA-48 producing Klebsiella pneumoniae using time-kill assays

2023

Conference Publication

A comparison of low-level to high-level disinfection in eliminating microorganisms from ultrasound transducers used on skin: a non-inferiority randomised controlled trial

Peters, Nathan, Williamson, Frances, Bauer, Michelle, Llewellyn, Stacey, Snelling, Peter, Marsh, Nicole, Harris, Patrick, Stewart, Adam and Rickard, Claire (2023). A comparison of low-level to high-level disinfection in eliminating microorganisms from ultrasound transducers used on skin: a non-inferiority randomised controlled trial. 2023 ACIPC International Conference, Adelaide, SA Australia, 12-15 November 2023. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.idh.2023.09.002

A comparison of low-level to high-level disinfection in eliminating microorganisms from ultrasound transducers used on skin: a non-inferiority randomised controlled trial

2023

Journal Article

The opportunities and challenges for artificial intelligence to improve sepsis outcomes in the paediatric intensive care unit

Aslan, Abdullah Tarik, Permana, Budi, Harris, Patrick N. A., Naidoo, Kuban D., Pienaar, Michael A. and Irwin, Adam D. (2023). The opportunities and challenges for artificial intelligence to improve sepsis outcomes in the paediatric intensive care unit. Current Infectious Disease Reports, 25 (11), 243-253. doi: 10.1007/s11908-023-00818-4

The opportunities and challenges for artificial intelligence to improve sepsis outcomes in the paediatric intensive care unit

Current funding

  • 2025 - 2026
    Breaking barriers: developing biofilm inhibitors to combat antimicrobial resistance (AEA externally led by La Trobe University)
    La Trobe University
    Open grant
  • 2025 - 2030
    Comparative effectiveness of Class II/III medical devices to prevent bloodstream infections in central venous catheters: The IVCare adaptive platform RCT
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2025 - 2030
    Henderson Foundation Fellowship
    The Henderson Foundation
    Open grant
  • 2025 - 2030
    Integrating sequencing technologies for bloodstream infection and sepsis diagnostics in critically-ill patients
    NHMRC MRFF Genomics Health Futures Mission
    Open grant
  • 2025 - 2030
    ROAD RCT: Resistance Optimised Antibiotic Dosing in critically ill patients - a Randomised Controlled Trial
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2025 - 2029
    New diagnostic strategies for antibiotic-resistant infections
    NHMRC Investigator Grants
    Open grant
  • 2024 - 2026
    Improved pathogen and antimicrobial resistance diagnostics in bloodstream infection and sepsis using a metagenomic approach (the META study)
    Study, education and research trust account
    Open grant
  • 2024 - 2026
    Testing EBL-1463 (a novel non-beta-lactam PBP inhibitor) against metallo-betalactamase producing Enterobacterales
    Mutabilis SAS
    Open grant
  • 2024 - 2026
    Reducing blood culture contamination with the use of a needle-less blood draw device (PIVO Pro): An adaptive group sequential randomized controlled trial (The PIVO Trial)
    Becton, Dickinson and Company
    Open grant
  • 2024 - 2028
    Unlocking the gut microbiome to track the spread of AMR genes and pathogens
    MRFF - Global Health Initiative
    Open grant
  • 2024 - 2025
    A Rapid, Routine Genomics Service for Clinical Haematology (QLD Health Targeted CRF led by RBWH Metro North Health)
    Metro North Hospital and Health Service
    Open grant
  • 2023 - 2026
    New diagnostic strategies for antibiotic-resistant infections
    Queensland Health Clinical Research Fellowships
    Open grant
  • 2023 - 2027
    Accelerating pathogen detection and antibiotic resistance prediction in children with suspected sepsis
    The Children's Hospital Foundation
    Open grant
  • 2018 - 2030
    Investigator Driven Randomized Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare Associated and Hospital Acquired Gram-negative Blood Stream Infection (the GAME CHANGER trial)
    Shionogi & Company, Limited
    Open grant

Past funding

  • 2023 - 2025
    Performance of emerging diagnostic techniques for the diagnosis of severe infections in neutropenic patients with haematological malignancies
    Microbio Ltd
    Open grant
  • 2023 - 2025
    Development of Wastewater-based epidemiology as a complementary approach for antimicrobial resistance surveillance
    Heidi-CSIRO IDR and AMR Projects
    Open grant
  • 2023 - 2024
    Improving management of fungal infections during blood cancer treatment
    Gilead Australia Fellowship
    Open grant
  • 2022 - 2024
    The 3,000 Genomes project: using machine learning and artificial intelligence for robust culture-independent susceptibility testing
    Heidi-CSIRO IDR and AMR Projects
    Open grant
  • 2022 - 2023
    Non-inferiority of low-level (LLD) versus high-level disinfection (HLD) for elimination of bacteria on contaminated ultrasound transducers: A randomised controlled trial (ASUM grant via MNHHS)
    Metro North Hospital and Health Service
    Open grant
  • 2022 - 2024
    Prediction of catheter associated bloodstream infection and hospital-onset sepsis events in critically ill adults
    Heidi-CSIRO IDR and AMR Projects
    Open grant
  • 2021 - 2022
    Improving Diagnosis, Management and Prevention of Invasive Meningococcal Disease
    Metro North Hospital and Health Service
    Open grant
  • 2021 - 2022
    Peripherally inserted central catheter Innovation to reduce Infections and Clots: the PICNIC trial
    NHMRC Project Grant
    Open grant
  • 2020 - 2021
    Assessing the epidemiology and variation of the variable virulence factor BimABM of Burkholderia pseudomallei in Queensland
    European Society of Clinical Microbiology and Infectious Diseases Study Group Research Grant
    Open grant
  • 2020 - 2021
    Assessing the effects of new and old antibiotics on gut microbiota of hospitalized patients
    Avant Mutual Group Limited
    Open grant
  • 2020
    Rapid detection of resistance genes from Gram-negative bacteria isolated from blood in ICU-admitted patients
    Pathology Queensland - Study, Education & Research Trust Fund
    Open grant
  • 2020 - 2021
    Assessing the effects of new and old antibiotics on the gut microbiome of hospitalized patients
    Metro North Hospital and Health Service
    Open grant
  • 2019 - 2022
    A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of ceftolozane-tazobactam versus meropenem for definitive treatment [...] MERINO-3
    Merck Sharp & Dohme Australia
    Open grant
  • 2019 - 2021
    Virulence and detection of Escherichia coli that cause neonatal meningitis
    The Children's Hospital Foundation
    Open grant
  • 2019 - 2021
    Rapid point-of-care tests for multidrug resistant bacteria tailored for QLD paediatrics
    The Children's Hospital Foundation
    Open grant
  • 2019 - 2022
    A multifaceted approach to the treatment and prevention of antibiotic-resistant bacterial infections
    NHMRC Early Career Fellowships
    Open grant
  • 2019 - 2023
    Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): A Randomized Controlled Clinical Trial (NHMRC Project Grant led by Monash University)
    Monash University
    Open grant
  • 2019 - 2021
    Peripherally inserted central catheter Innovation to reduCe Infections and Clots: the PICNIC trial (NHMRC Project Grant led by Griffith University)
    Griffith University
    Open grant
  • 2019 - 2020
    Rapid detection of resistance genes from gram-negative bacteria isolated from blood in ICU-admitted patients to enable timely and effective treatment
    Metro North Hospital and Health Service
    Open grant
  • 2018 - 2023
    Cluster randomised trial of a multimodal intervention to reduce antimicrobial use in residential aged care facilities
    NHMRC MRFF - Antimicrobial Resistance Targeted Call for Research
    Open grant
  • 2018 - 2019
    Evaluation of cefiderocol (S-649266) against Burkholderia pseudomallei isolates from Queensland, Australia
    Shionogi & Company, Limited
    Open grant
  • 2018
    Rapid characterisation of pathogens for personalised antimicrobial selection in critically ill patients
    Metro North Hospital and Health Service
    Open grant
  • 2017 - 2018
    Pilot Randomised Controlled Trial of Penicillin versus Flucloxacillin for Definitive Treatment of Invasive Penicillin susceptible Staphylococcus aureas
    Metro North Hospital and Health Service
    Open grant
  • 2015
    Pilot randomised controlled trial of meropenem versus piperacillin-tazobactam for the definitive treatment of bloodstream infections caused by AmpC beta-lactamase producing Enterobacter spp, ...
    Royal Brisbane and Women's Hospital
    Open grant

Availability

Dr Patrick Harris is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    New diagnostic strategies for antibiotic-resistant infections

    Principal Advisor

    Other advisors: Associate Professor Adam Irwin, Dr Brian Forde

  • Doctor Philosophy

    Novel trial design in evaluation of antibiotics.

    Associate Advisor

    Other advisors: Mr Mark Chatfield

  • Doctor Philosophy

    Early impact antibiotic therapy for carbapenem resistant organisms, guided by rapid diagnostics

    Associate Advisor

  • Doctor Philosophy

    Clinical and laboratory applications of new and emerging methods of diagnosis of infection

    Associate Advisor

  • Doctor Philosophy

    Clinical epidemiology and treatment of central nervous system infections in Asia

    Associate Advisor

  • Doctor Philosophy

    Accelerating pathogen detection and antibiotic resistance prediction in children with suspected sepsis.

    Associate Advisor

    Other advisors: Associate Professor David Whiley, Associate Professor Adam Irwin

  • Doctor Philosophy

    Genomic approaches to the surveillance and control of multidrug resistant Enterobacterales.

    Associate Advisor

    Other advisors: Dr Brian Forde

Completed supervision

Enquiries

For media enquiries about Dr Patrick Harris's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au